GlobalData spotlighted Roche’s Ocrevus and Novartis’ Kesimpta as leaders in the space; Ocrevus, in particular, is expected to reel in more than $8 billion in sales this year, representing ...

The new data presented by Novartis at ECTRIMS 2022 highlighted the safety and efficacy of Kesimpta and supported its use as an early intervention treatment option, as well as demonstrating high ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

Novartis hat auch in der Schweiz die Zulassung für das Krebsmedikament Kisqali erhalten. So habe Swissmedic das Mittel zur ...

Novartis' balance sheet strengthens amid continued strong demand for Entresto, Kesimpta, and Kisqali Novartis' revenue was about $13.15 billion in the fourth quarter of 2024, up 15.1% year-over ...

The global central nervous system (CNS) market is projected grow to over $80 billion in sales in 2025 for the first time ...

Der Pharmakonzern Novartis stellt an einem Branchenkongress neue Daten zum Medikament Kesimpta gegen Multiple Sklerose vor.

Novartis has performed well in the previous ... Key drugs like Kisqali (breast cancer), Kesimpta (multiple sclerosis), Scemblix (chronic myeloid leukemia or CML), Pluvicto (prostate cancer ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

Novartis stock closed relatively flat Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto. Entresto is Novartis' biggest moneymaker.